Connor, Clark & Lunn Investment Management Ltd. Affimed N.V. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 05, 2022	SELL	$2.27 - $4.86 $416,642 - $892,018	-183,543 Reduced 78.68%	49,723 $138,000
Q1 2022 May 12, 2022	SELL	$3.69 - $5.65 $793,619 - $1.22 Million	-215,073 Reduced 47.97%	233,266 $1.02 Million
Q4 2021 Feb 10, 2022	BUY	$5.37 - $7.07 $5,917 - $7,791	1,102 Added 0.25%	448,339 $2.48 Million
Q3 2021 Nov 12, 2021	BUY	$5.54 - $7.51 $1.57 Million - $2.13 Million	283,833 Added 173.7%	447,237 $2.76 Million
Q2 2021 Aug 12, 2021	BUY	$7.78 - $11.4 $144,241 - $211,356	18,540 Added 12.8%	163,404 $1.39 Million
Q1 2021 May 13, 2021	BUY	$5.12 - $8.48 $620,723 - $1.03 Million	121,235 Added 513.08%	144,864 $1.15 Million
Q4 2020 Feb 16, 2021	BUY	$3.16 - $7.03 $74,667 - $166,111	23,629 New	23,629 $138,000
Q2 2020 Aug 13, 2020	SELL	$1.58 - $4.63 $82,316 - $241,218	-52,099 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$1.44 - $3.02 $37,078 - $77,761	25,749 Added 97.72%	52,099 $82,000
Q4 2019 Feb 12, 2020	SELL	$2.25 - $3.07 $3,150 - $4,298	-1,400 Reduced 5.05%	26,350 $72,000
Q3 2019 Nov 13, 2019	SELL	$2.67 - $3.65 $82,775 - $113,157	-31,002 Reduced 52.77%	27,750 $82,000
Q2 2019 Aug 07, 2019	BUY	$2.6 - $4.21 $152,755 - $247,345	58,752 New	58,752 $169,000

Others Institutions Holding AFMD

# of Institutions

Shares Held

1.09M

Call Options Held

Put Options Held

Tekla Capital Management LLC

586K
Shares

$2.04 Million
0.01% of portfolio
Act Capital Management, LLC Wayne, PA

309K
Shares

$1.07 Million
0.88% of portfolio
Telemetry Investments, L.L.C. New York, NY

200K
Shares

$696,000
0.39% of portfolio

View Full List

About Affimed N.V.

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

More about AFMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account